Eli Lilly (LLY, Financial) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly's weight-loss drug Zepbound (tirzepatide) just proven to be more effective than Novo Nordisk's Wegovy
(semaglutide) in losing body weight.
Zepbound is primarily targeted at adults living with obesity or overweight who have at least one weight-related
comorbidity, such as hypertension, dyslipidemia, obstructive sleep apnea (OSA), or cardiovascular disease.
Zepbound is currently in Phase 3b of clinical trials meaning that It's a head-to-head study comparing the efficacy and safety of tirzepatide (Zepbound) to semaglutide (Wegovy) in adults with obesity or overweight who have at least one weight-related comorbidity, but without diabetes. And the trial showed that Zepbound led to a 47% greater relative weight loss compared to Wegovy.
Patients on Zepbound lost an average of 20.2% of their body weight compared to 13.7% for those on Wegovy.
We have now heard some pharmaceuticals developing treatments for obesity as it's now considered as a disease. Eli Lilly and Novo Nordisk are just two players in this field, other players include: Amgen that is now
developing MariTide, an experimental drug for diabetes and obesity, there's also Viking Therapeutics (VKTX, Financial) that is now working on VK2735, an oral and injectable weight-loss drug, Structure Therapeutics is also developing an oral GLP-1 drug GSBR-1290 for weight loss.
The lucrative weight-loss market lured these companies to address global health issue that is caused by bad eating habit that becomes popular lifestyle.
